NetScientific PLC PDS Biotechnology partners with NCI (5158O)
09 Fevereiro 2016 - 9:05AM
UK Regulatory
TIDMNSCI
RNS Number : 5158O
NetScientific PLC
09 February 2016
NetScientific plc
PDS Biotechnology partners with National Cancer Institute in
Phase II clinical trials for novel cancer immunotherapies
London, UK - 9 February 2016 - NetScientific plc
("NetScientific" or the "Group", AIM: NSCI), the transatlantic
biomedical and healthcare technology group, is pleased to note that
one of its portfolio companies, PDS Biotechnology, has signed a
Cooperative Research and Development Agreement with the National
Cancer Institute, a division of the US National Institutes of
Health. The goal is to co-develop novel cancer immunotherapies
through Phase II clinical trials that will start in 2016 and
2017.
Commenting on the news, NetScientific's Chief Executive Officer,
Francois R. Martelet said: "Securing a cooperative research and
development agreement with the leading cancer research institute in
the US is a landmark moment for PDS Biotechnology and a huge
endorsement of its technology. Versamune(R) has been shown to be
applicable to potentially a wide range of cancers and this deal
will be key to further advancing immunotherapy clinical
research."
The full text of the announcement from PDS Biotechnology can be
found below.
Contact Details
NetScientific Tel: +44 (0)20 3514
François R. Martelet, 1800
M.D., CEO
Mark Nanovich, Interim
CFO
Tel: +44 (0)20 7597
Investec (NOMAD and broker) 4000
Gary Clarence / Daniel
Adams
Tel: +44 (0)20 7457
Instinctif Partners 2020 Email: netscientific@instinctif.com
Melanie Toyne-Sewell
/ Jayne Crook / Rosanna
Forrest
PDS Biotechnology Signs Agreement with National Cancer Institute
to form Phase II clinical collaboration for novel cancer
immunotherapies based on PDS' Versamune(R) platform technology
-Clinical Co-Development of Immunotherapies to treat Prostate,
Breast, and HPV-related Cancers-
North Brunswick, New Jersey February 9, 2016 (PR NEWSWIRE) - PDS
Biotechnology (PDS), a clinical-stage biopharmaceutical company
focused on developing a pipeline of simpler, safer and more
effective cancer immunotherapies based on its novel Versamune(R)
platform, today announced that the Company has signed a Cooperative
Research and Development Agreement (CRADA) with the National Cancer
Institute (NCI), an Institute of the U.S. National Institutes of
Health. Under the CRADA, PDS and NCI aim to co-develop several
immunotherapies through Phase II clinical trials to be initiated in
2016 and 2017, utilizing combinations of Versamune(R) with NCI- and
PDS-sourced tumor-related proteins or their fragments recognized by
the immune system (antigens) in prostate, breast, and HPV-related
cancers.
The PDS-NCI CRADA collaboration is led by Jay A. Berzofsky,
M.D., Ph.D., Chief of the NCI Center for Cancer Research (CCR)
Vaccine Branch, Lauren V. Wood, M.D., Head of the NCI CCR Vaccine
Branch Clinical Trials Team, and Masaki Terabe, Ph.D., Deputy
Section Chief of the NCI CCR Vaccine Branch. The CRADA encompasses
Phase II clinical development, starting in late 2016, of
antigen-specific immunotherapies for multiple cancers, as well as
additional preclinical studies combining the Versamune(R) platform
with specific technologies to generate potent antigen-specific and
natural killer T-cell anti-tumor immune responses.
"The Versamune(R) platform, based on preclinical and Phase I
human clinical studies, has demonstrated the potential to overcome
the most critical obstacles facing cancer vaccine technologies.
Versamune(R) enables the design of simple subcutaneous
immunotherapies that efficiently deliver tumor antigens to the
patient's own immune system, while simultaneously stimulating the
generation of potent tumor-killing T-cells that can overcome the
tumor's immuno-suppressive environment. We are very pleased to have
the opportunity to collaborate with Drs. Berzofsky, Wood, and
Terabe, to extend the clinical progress that has been achieved to
date with our Versamune(R) platform and the immunotherapy field in
general" said Frank Bedu-Addo, Ph.D., PDS's President and Chief
Executive Officer.
About Versamune(R):
Versamune(R) is a clinical stage and synthetic lipid-based
immunotherapy platform. Due to its unusual combination of high
safety and potent killer (CD8+) T-cell induction in humans,
Versamune(R) has demonstrated the potential to achieve a key goal
of cancer immunotherapy: to effectively prevent and treat cancer in
its most treatable early stages. Versamune(R) is unique in its
demonstrated potential to activate all three critical immunotherapy
mechanisms, improving the potential for effective anti-tumor effect
upon simple subcutaneous injection. The Versamune(R) platform is
now being applied to the development of multiple Phase II
clinical-stage cancer products, including both early and late-stage
cancer indications.
About PDS Biotechnology
PDS Biotechnology is a private biopharmaceutical company with a
growing pipeline of simpler, safer, and more effective
clinical-stage immunotherapies to treat various early-stage and
late-stage cancers. PDS is completing its first oncology human
clinical trial and expects to report these Phase I study results in
the very near future. PDS is also applying the versatile
Versamune(R) platform to the prevention of selected pandemic
diseases.
About NetScientific
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment.
For more information, please visit the website at
www.netscientific.net.
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAKCDDKBKDPBK
(END) Dow Jones Newswires
February 09, 2016 06:05 ET (11:05 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024